These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27004749)

  • 1. Unusual case of tacrolimus vascular toxicity after deceased donor renal transplantation.
    Sugitani A; Takahashi C; Naka T; Hisamitsu K; Yamamoto O; Taniguchi K; Kobayashi N; Kimura M; Yoshida H; Hamazoe R
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():60-2. PubMed ID: 27004749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological analyses of chronic vascular rejection after kidney transplantation.
    Shimizu T; Toma H; Shibahara R; Tsunoyama K; Izuka J; Nozaki T; Ishida H; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():20-5. PubMed ID: 26031581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
    Alhamad T; Venkatachalam K; Daloul R; Brennan DC; Malone AF
    Transplantation; 2017 Aug; 101(8):e287-e288. PubMed ID: 28422926
    [No Abstract]   [Full Text] [Related]  

  • 6. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
    Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
    Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
    Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological findings in non-episode biopsies of kidney transplant allografts treated with FK506 or cyclosporine.
    Kyo M; Hatori M; Takahara S; Kyakuno M; Nakamura T; Okada M; Kokado Y; Toki K; Ding XQ; Miki T; Miyamoto M; Okuyama A
    Transpl Int; 1998; 11 Suppl 1():S100-3. PubMed ID: 9664955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation.
    Borda B; Lengyel C; Várkonyi T; Kemény E; Ottlakán A; Kubik A; Keresztes C; Lázár G
    Acta Physiol Hung; 2014 Sep; 101(3):388-94. PubMed ID: 25183511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living-Donor Kidney Transplant-Associated Thrombotic Microangiopathy Successfully Treated With Thymoglobulin: A Case Report.
    Akl A; Alobaidi S; Aboalsamh G
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):175-177. PubMed ID: 30777549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in kidney transplant biopsies.
    Kumar A; Hammad A; Sharma AK; Mc-Cardle F; Rustom R; Christmas SE
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():207-13. PubMed ID: 25894156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altitude and arteriolar hyalinosis after kidney transplantation.
    Cippà PE; Grebe SO; Fehr T; Wüthrich RP; Mueller TF
    Nephrology (Carlton); 2016 Sep; 21(9):782-4. PubMed ID: 26823025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Stratification for Rejection and Infection after Kidney Transplantation.
    Cippà PE; Schiesser M; Ekberg H; van Gelder T; Mueller NJ; Cao CA; Fehr T; Bernasconi C
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2213-20. PubMed ID: 26430088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
    Trials; 2015 Mar; 16():118. PubMed ID: 25873064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.